ホーム>>Signaling Pathways>> Tyrosine Kinase>> Trk>>Bedinvetmab

Bedinvetmab

カタログ番号GC72353

Bedinvetmab(ZTS-00508841)は、神経成長因子(NGF)に対するイヌモノクローナル抗体(mAb)である。

Products are for research use only. Not for human use. We do not sell to patients.

Bedinvetmab 化学構造

Cas No.: 2171034-69-6

サイズ 価格 在庫数 個数
1 mg
$270.00
在庫あり
5 mg
$702.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs.

Bedinvetmab (0.5-1 mg/kg; s.c. for 28 d) alleviates the pain associated with canine osteoarthritis[1].
Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) is well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration[2].

References:
[1]. Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955.
[2]. Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733.

レビュー

Review for Bedinvetmab

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bedinvetmab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.